218 related articles for article (PubMed ID: 15753738)
1. Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients.
Shermock KM; Horn E; Lipsett PA; Pronovost PJ; Dorman T
Crit Care Med; 2005 Mar; 33(3):497-503. PubMed ID: 15753738
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietic agents for anemia of critical illness.
Shermock KM; Horn E; Rice TL
Am J Health Syst Pharm; 2008 Mar; 65(6):540-6. PubMed ID: 18319499
[TBL] [Abstract][Full Text] [Related]
3. Avoiding a blood transfusion: How much is it worth?
Corwin HL; Hebert P
Crit Care Med; 2005 Mar; 33(3):672-4. PubMed ID: 15753765
[No Abstract] [Full Text] [Related]
4. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of epoetin and autologous blood donationin reducing allogeneic blood transfusions incoronary artery bypass graft surgery.
Marchetti M; Barosi G
Transfusion; 2000 Jun; 40(6):673-81. PubMed ID: 10864987
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients.
MacLaren R; Sullivan PW
Value Health; 2005; 8(2):105-16. PubMed ID: 15804319
[TBL] [Abstract][Full Text] [Related]
7. Anemia in the critically ill.
Shander A
Crit Care Clin; 2004 Apr; 20(2):159-78. PubMed ID: 15135458
[TBL] [Abstract][Full Text] [Related]
8. Potential cost saving of Epoetin alfa in elective hip or knee surgery due to reduction in blood transfusions and their side effects: a discrete-event simulation model.
Tomeczkowski J; Stern S; Müller A; von Heymann C
PLoS One; 2013; 8(9):e72949. PubMed ID: 24039829
[TBL] [Abstract][Full Text] [Related]
9. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
Naci H; de Lissovoy G; Hollenbeak C; Custer B; Hofmann A; McClellan W; Gitlin M
J Med Econ; 2012; 15(2):293-304. PubMed ID: 22115328
[TBL] [Abstract][Full Text] [Related]
10. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia.
Sheffield R; Sullivan SD; Saltiel E; Nishimura L
Ann Pharmacother; 1997 Jan; 31(1):15-22. PubMed ID: 8997459
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial.
Corwin HL; Gettinger A; Rodriguez RM; Pearl RG; Gubler KD; Enny C; Colton T; Corwin MJ
Crit Care Med; 1999 Nov; 27(11):2346-50. PubMed ID: 10579246
[TBL] [Abstract][Full Text] [Related]
12. Anemia in the critically ill: the role of erythropoietin.
Corwin HL
Semin Hematol; 2001 Jul; 38(3 Suppl 7):24-32. PubMed ID: 11523025
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of recombinant human erythropoietin versus transfusions in the treatment of zidovudine-related anemia in HIV-infected children.
Allen UD; Kirby MA; Goeree R
Pediatr AIDS HIV Infect; 1997 Feb; 8(1):4-11. PubMed ID: 11361510
[TBL] [Abstract][Full Text] [Related]
14. Recombinant erythropoietin and blood transfusions in cancer chemotherapy-induced anemia.
Griggs JJ; Blumberg N
Anticancer Drugs; 1998 Nov; 9(10):925-32. PubMed ID: 9890704
[TBL] [Abstract][Full Text] [Related]
15. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities.
House AA; Pham B; Pagé DE
Nephrol Dial Transplant; 1998 Jul; 13(7):1763-9. PubMed ID: 9681725
[TBL] [Abstract][Full Text] [Related]
16. Analysis of economic and social costs of adverse events associated with blood transfusions in Spain.
Ribed-Sánchez B; González-Gaya C; Varea-Díaz S; Corbacho-Fabregat C; Bule-Farto I; Pérez de-Oteyza J
Gac Sanit; 2018; 32(3):269-274. PubMed ID: 29459107
[TBL] [Abstract][Full Text] [Related]
17. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.
Ohlsson A; Aher SM
Cochrane Database Syst Rev; 2006 Jul; (3):CD004863. PubMed ID: 16856062
[TBL] [Abstract][Full Text] [Related]
18. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group.
Maier RF; Obladen M; Scigalla P; Linderkamp O; Duc G; Hieronimi G; Halliday HL; Versmold HT; Moriette G; Jorch G
N Engl J Med; 1994 Apr; 330(17):1173-8. PubMed ID: 8139627
[TBL] [Abstract][Full Text] [Related]
19. Blood conservation strategies to reduce the need for red blood cell transfusion in critically ill patients.
Tinmouth AT; McIntyre LA; Fowler RA
CMAJ; 2008 Jan; 178(1):49-57. PubMed ID: 18166731
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia.
Barosi G; Marchetti M; Liberato NL
Br J Cancer; 1998 Sep; 78(6):781-7. PubMed ID: 9743301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
